Skip to main content

Research Repository

Advanced Search

All Outputs (2)

Abstract A020: Calcitonin receptor-like receptor is expressed in blood vessels in clear cell renal cell carcinoma and upregulated in endothelial cells co-cultured with tumor cells (2023)
Presentation / Conference Contribution
Morfitt, M. A., Greenman, J., Maraveyas, A., Harris, A. L., & Nikitenko, L. L. (2023). Abstract A020: Calcitonin receptor-like receptor is expressed in blood vessels in clear cell renal cell carcinoma and upregulated in endothelial cells co-cultured with tumor cells. Cancer Research, 83(16_Supplement), A020-A020. https://doi.org/10.1158/1538-7445.kidney23-a020

Introduction. Clear cell renal cell carcinoma (ccRCC) is a highly vascularized and clinically aggressive kidney cancer, with high rates of metastasis and recurrence after cytoreductive nephrectomy. ccRCC can be treated with anti-angiogenic drugs, how... Read More about Abstract A020: Calcitonin receptor-like receptor is expressed in blood vessels in clear cell renal cell carcinoma and upregulated in endothelial cells co-cultured with tumor cells.

Abstract B001: Calcitonin receptor-like receptor agonists induce p44/42 MAPK phosphorylation in VEGF-A-stimulated human blood endothelial cells after bevacizumab treatment (2023)
Presentation / Conference Contribution
Morfitt, M. A., Greenman, J., Maraveyas, A., & Nikitenko, L. L. (2023). Abstract B001: Calcitonin receptor-like receptor agonists induce p44/42 MAPK phosphorylation in VEGF-A-stimulated human blood endothelial cells after bevacizumab treatment. Cancer Research, 83(16_Supplement), B001-B001. https://doi.org/10.1158/1538-7445.kidney23-b001

Introduction. Clear cell renal cell carcinoma (ccRCC) is a highly vascularized and clinically aggressive cancer. In the UK, there are around 9000 diagnoses and 3000 deaths annually. Targeted therapies that inhibit angiogenic regulators, such as bevac... Read More about Abstract B001: Calcitonin receptor-like receptor agonists induce p44/42 MAPK phosphorylation in VEGF-A-stimulated human blood endothelial cells after bevacizumab treatment.